Scientists have revealed that they are making progress towards new antimalarial drugs, after revealing how an antibiotic called emetine blocks the molecular machinery that produces the proteins required for malaria parasite survival.
Although emetine is effective against malaria it is not used as a preventive drug due to its significant side effects, but Dr Wilson Wong and his colleagues have shown how emetine attaches to and blocks the molecular machinery that makes the proteins required for malaria parasite survival has revealed new approaches for antimalarial drug development.
Dr Wong said that the study examined the parasite cell's protein-making machinery, called the ribosome, visualising for the first time the structure of this 'protein complex' in the malaria parasite.
The ribosome is responsible for constructing all proteins inside the cell, based on the DNA 'blueprint'. Antibiotics such as emetine kill the malaria parasite by binding to its ribosome and preventing the parasite from building the proteins it needs to produce energy, grow, reproduce and evade the immune system.
The study was published in the journal eLife.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
